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P A Ioannidis,5,6,7 Harry Campbell,1 Evropi Theodoratou1,2 
ABSTRACT
ObjeCtive
To map the diverse health outcomes associated with 




Medline, Embase, Cochrane Database of Systematic 
Reviews, and screening of citations and references.
eligibility Criteria
Systematic reviews and meta-analyses of 
observational studies that examined associations 
between SUA level and health outcomes, meta-
analyses of randomised controlled trials that 
investigated health outcomes related to SUA lowering 
treatment, and Mendelian randomisation studies that 
explored the causal associations of SUA level with 
health outcomes.
results
57 articles reporting 15 systematic reviews and144 
meta-analyses of observational studies (76 unique 
outcomes), 8 articles reporting 31 meta-analyses of 
randomised controlled trials (20 unique outcomes), and 
36 articles reporting 107 Mendelian randomisation 
studies (56 unique outcomes) met the eligibility criteria. 
Across all three study types, 136 unique health outcomes 
were reported. 16 unique outcomes in meta-analyses of 
observational studies had P<10-6, 8 unique outcomes in 
meta-analyses of randomised controlled trials had 
P<0.001, and 4 unique outcomes in Mendelian 
randomisation studies had P<0.01. Large between study 
heterogeneity was common (80% and 45% in meta-
analyses of observational studies and of randomised 
controlled trials, respectively). 42 (55%) meta-analyses 
of observational studies and 7 (35%) meta-analyses of 
randomised controlled trials showed evidence of small 
study effects or excess significance bias. No 
associations from meta-analyses of observational 
studies were classified as convincing; five associations 
were classified as highly suggestive (increased risk of 
heart failure, hypertension, impaired fasting glucose or 
diabetes, chronic kidney disease, coronary heart 
disease mortality with high SUA levels). Only one 
outcome from randomised controlled trials (decreased 
risk of nephrolithiasis recurrence with SUA lowering 
treatment) had P<0.001, a 95% prediction interval 
excluding the null, and no large heterogeneity or bias. 
Only one outcome from Mendelian randomisation 
studies (increased risk of gout with high SUA levels) 
presented convincing evidence. Hypertension and 
chronic kidney disease showed concordant evidence in 
meta-analyses of observational studies, and in some 
(but not all) meta-analyses of randomised controlled 
trials with respective intermediate or surrogate 
outcomes, but they were not statistically significant in 
Mendelian randomisation studies.
COnClusiOn
Despite a few hundred systematic reviews, meta-
analyses, and Mendelian randomisation studies 
exploring 136 unique health outcomes, convincing 
evidence of a clear role of SUA level only exists for gout 
and nephrolithiasis.
Introduction
Uric acid was thought to be a biologically inert waste 
product from purine metabolism, until in the early 1800s 
it was discovered that an increased serum uric acid (SUA) 
level was the cause of gout.1  Subsequently, associations 
of uric acid concentration with cardiovascular and renal 
disorders were also observed.2  These associations were 
explored in several prospective studies but yielded con-
flicting results, and therefore the causal role of uric acid 
in these diseases was widely questioned.3-6  It was argued 
that these associations are either confounded by other 
risk factors, such as obesity and hypertension, or are rep-
resentative of reverse causality.4 7  These inconclusive 
findings led to a shift of interest away from uric acid, and 
asymptomatic hyperuricemia was not considered as an 
indication for SUA lowering treatment in patients with 
cardiovascular and renal diseases.8 9
New findings have fuelled enthusiasm to address this 
longstanding controversy.10  Recent epidemiological 
WhAT IS AlReAdy knoWn on ThIS TopIC
Observational studies suggest that high serum uric acid (SUA) levels are associated 
with multiple health outcomes, including cardiovascular and metabolic diseases 
(increased risk) or neurological diseases (decreased risk), yet it remains to be 
determined whether these observed associations are causal
Clinical trials of SUA lowering have shown that xanthine oxidase inhibition 
decreases blood pressure and improves renal function
There is still debate as to whether SUA level is simply a marker of xanthine oxidase 
activity or a causal factor involved in systemic inflammation
WhAT ThIS STudy AddS
Of the 136 health outcomes related to SUA level that were examined in meta-
analyses of observational studies, meta-analyses of randomised controlled trials, 
and Mendelian randomisation studies, convincing evidence of a clear association 
exists only for gout and nephrolithiasis
The available evidence does not support any change in the existing clinical 
recommendations in relation to hyperuricemia
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studies have explored associations of uric acid with a 
wide range of conditions (cardiovascular diseases, met-
abolic syndrome, diabetes, and cancer) and some inter-
mediate phenotypes or biomarkers.11  In an attempt to 
understand the possible underlying mechanisms, labo-
ratory studies have been carried out and found that uric 
acid is potentially involved in multiple biological pro-
cesses, including oxidative stress, systemic inflamma-
tion, and intrahepatic fructose metabolism, all 
mechanisms that could be linked to the development of 
cardiovascular disease and metabolic syndrome.12-14 
Alternatively, uric acid level may only present a marker 
of high oxidative stress associated with increased xan-
thine oxidase activity, instead of being an active agent 
in the pathogenic processes.15  Finally, taking into 
account the antioxidant properties of uric acid (acting 
as a free radical scavenger), its potential mechanistic 
roles in these disorders may be complex.16
In view of the potential importance of uric acid, 
assessing the credibility of the observed evidence may 
have implications both for clinical practice and public 
health. It is recognised that different types of studies 
have specific strengths and weaknesses that can be 
complementary (see box 1). An umbrella review, which 
collects and evaluates evidence from multiple resources 
systematically, might therefore help clarify the compos-
ite literature. We carried out an umbrella review of 
meta-analyses of observational studies, meta-analyses 
of randomised controlled trials, and Mendelian rando-
misation studies on associations between SUA level and 
multiple health outcomes. In particular, we sum-
marised the range of related health outcomes, pre-
sented the magnitude, direction, and significance of the 
reported associations and effects, assessed the poten-
tial biases, and identified which associations and 
effects have the most convincing evidence.
Methods
literature search and selection criteria
We systematically searched Medline, Embase, and the 
Cochrane Database of Systematic Reviews from incep-
tion to 17 July 2016 using a comprehensive search strat-
egy (see table S1 in the web appendix) to identify 
systematic reviews and meta-analyses of observational 
studies, meta-analyses of randomised controlled trials, 
and Mendelian randomisation studies. All identified 
publications went through a three step parallel review of 
title, abstract, and full text (performed by XL and XM) 
based on predefined inclusion and exclusion criteria.
We included systematic reviews and meta-analyses of 
observational studies that examined associations 
between serum uric acid (SUA) levels (or hyperurice-
mia) and health outcomes; meta-analyses of ran-
domised controlled trials that investigated health 
outcomes related to SUA lowering treatment (interven-
tion with one or a combination of two or more SUA low-
ering drugs versus placebo or no treatment), including 
xanthine oxidase inhibitors (allopurinol, febuxostat, or 
oxypurinol), uricosuric agents (probenecid, benzbro-
marone, thiazides, or citrates), and uricase analogues 
(pegloticase or rasburicase); and Mendelian randomis-
ation studies that explored SUA (or hyperuricemia) 
associations in relation to health outcomes by using 
genetic instruments influencing SUA levels. The identi-
fied health outcomes included a wide range of diseases, 
intermediate phenotypes, and biomarkers. We excluded 
studies investigating associations between gout and 
health outcomes and meta-analyses of randomised con-
trolled trials that used non-drug interventions, such as 
dietary or lifestyle interventions. We further excluded 
animal and laboratory studies, meta-analyses on the 
prevalence of gout and hyperuricemia, and meta-anal-
yses of randomised controlled trials that focused on 
drug variables, safety, and effects of reducing SUA lev-
els without investigating other health effects.
Data extraction
One investigator (XL) extracted data, which were checked 
by a second investigator (XM). For each eligible study, we 
extracted the PubMed identification number, lead 
author’s name, journal name, publication year, study 
population, number of studies included, and outcomes 
investigated. For meta-analyses investigating more than 
one health outcome, we recorded each outcome sepa-
rately. For meta-analyses of observational studies and of 
randomised controlled trials, we extracted the reported 
summary risk estimates (risk ratio, odds ratio, hazard 
ratio, or mean difference) with the 95% confidence inter-
vals and the corresponding number of case and control 
participants. Furthermore, for each unique outcome we 
box 1: strengths and limitations of study types
Although none of the following study types are infallible, all are able to provide useful 
information about causal inference and can complement each other to achieve 
increasing certainty about causality
Observational studies
•	Aim to examine the association between an exposure and an outcome and to test 
whether the association is caused by chance, bias, or confounding
•	Typically are affected by residual confounding, undetected bias, or reverse 
causality, which may generate associations that are not reliable indicators of 
causality
randomised controlled trials
•	An approach to obtain evidence of a causal effect of a treatment or intervention on a 
disease process
•	Eliminates many of the biases and confounding factors that are present in 
observational studies
•	Limitations include non-adherence to the assigned intervention, limited external 
validity, short term intervention effects, and non-retention, which can all render the 
results invalid or questionable
•	High costs and ethical concerns can also limit the application of the trials in 
scientific research
Mendelian randomisation studies
•	Provide a cost effective analogy to a randomised controlled trial by using genetic 
variants as proxies to test the causality of an association between exposure and 
outcome
•	 Is not influenced by the confounding inherent in observational studies and not 
seriously affected by reverse causality, but does rely on several assumptions (the 
genetic instruments should be associated with the exposure of interest, they 
should not be associated with known confounders, and they should affect the 
outcome solely through the exposure) that can be hard to identify and control
•	May lack power when the proportion of trait variance explained by the genetic 
instruments is small
the bmj | BMJ 2017;357:j2376 | doi: 10.1136/bmj.j2376
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extracted data from the individual component studies 
that were included in the meta-analyses for further anal-
ysis. This second level extraction included data on study 
design, number of cases, total number of participants, 
relative risk estimates, and 95% confidence intervals for 
each component study. When more than one meta-analy-
sis existed for the same outcome in the same population, 
we extracted individual component data from the most 
recent and largest meta-analysis. In a few exceptions 
where the most recent was not also the largest meta-anal-
ysis, we explored the reason for this discrepancy. If the 
most recent included prospective studies and the largest 
one had fewer prospective studies plus some retrospec-
tive data, we kept the one with the largest amount of pro-
spective data; otherwise we kept the largest meta-analysis. 
For Mendelian randomisation studies, we extracted data 
on study population, sample size, genetic instruments, 
the variance of SUA level explained by the genetic instru-
ments (R2) and Mendelian randomisation effect estimates 
(odds ratio, hazard ratio, mean difference, or regression 
coefficient β), standard deviation of SUA levels, and stan-
dard deviation of continuous outcomes.
Data analysis
For systematic reviews we performed descriptive analy-
ses and presented the authors’ conclusions. For each 
unique meta-analysis of observational studies and of 
randomised controlled trials, we estimated several met-
rics, including the summary effect and 95% confidence 
intervals using a random effect model (DerSimonian 
Laird method)17; the heterogeneity among studies (Q 
statistic and I2 metric with 95% confidence intervals); 
the 95% prediction interval to predict the range of effect 
size that would be expected in a new original study, 
after accounting for both the heterogeneity among indi-
vidual studies and the uncertainty of the summary 
effect estimated in the random effect model (the calcu-
lation of 95% prediction interval is based on the pre-
dicted distribution derived from a function of the degree 
of heterogeneity, number of studies included, and 
within study standard errors)18 19 ; the presence of small 
study effects by using the Egger’s regression asymmetry 
test to investigate if small studies tend to give larger 
estimates of effect size than large studies (significance 
threshold P<0.10)20; and the excess significance test to 
assess if the observed number (O) of studies with signif-
icant results was greater than the expected number (E) 
using the χ2 test: A=[(O−E)2/E+(O−E)2/(n−E)] (signifi-
cance threshold P<0.10).21 22 For the excess significance 
test, we calculated the expected number (E) of studies 
with significant findings by using the sum of statistical 
power estimated for each component study. The 
 statistical power of each component study was calcu-
lated with an algorithm that uses a non-central t distri-
bution, by assuming the true effect size to be the same 
as that of the largest component study (with smallest 
variance) in the meta-analysis.23  If the type of metric in 
a meta-analysis was mean difference, we firstly calcu-
lated Cohen’s d by weighing the pooled standard devia-
tion based on the sample size of individual studies. We 
then transformed Cohen’s d, Hedges g, and other 
 standardised mean difference metrics to odds ratios.24 
We compared the results reported in overlapping 
meta-analyses to evaluate their concordance in terms of 
the direction and statistical significance of the observed 
associations. All statistical analyses were conducted in 
Stata (StataCorp) version 14.0.
Owing to the extensive differences in genetic instru-
ments used in the Mendelian randomisation studies we 
did not conduct quantitative syntheses. Instead, we 
performed and present here a descriptive analysis of the 
individual studies. When more than one Mendelian 
randomisation study was conducted for the same out-
come, we compared the concordance of the findings for 
the direction and statistical significance of the reported 
association and retained the study with the largest 
number of cases and participants for further analysis 
and comparison. If all of the information required for 
calculation was provided (ie, sample size, number of 
cases, R2, estimates of association, standard deviation 
of continuous outcomes, and standard deviation of SUA 
levels), we performed a power calculation for the larg-
est Mendelian randomisation studies by using the 
non-centrality parameter based approach.25 For Mende-
lian randomisation studies with missing R2 values, we 
performed a crude power estimation by using the R2 
values from other Mendelian randomisation studies 
that used the same genetic variants as instruments.
Credibility assessment
As previously proposed,26 we classified evidence from 
meta-analyses of observational studies with nominally 
statistically significant summary results (P<0.05) into 
four categories (class I, II, III, and IV). Convincing (class 
I) evidence was assigned to associations with a statisti-
cal significance of P<10−6, included more than 1000 
cases (or more than 20 000 participants for continuous 
outcomes), had the largest component study reporting a 
significant result (P<0.05), had a 95% prediction interval 
that excluded the null, did not have large heterogeneity 
(I2 <50%), and showed no evidence of small study effects 
(P>0.10) and of excess significance bias (P>0.10). Highly 
suggestive (class II) evidence was assigned to associa-
tions that reported a significance of P<0.001, included 
more than 1000 cases (or more than 20 000 participants 
for continuous outcomes), and had the largest compo-
nent study reporting a statistically significant result 
(P<0.05). Suggestive (class III) evidence was assigned to 
associations that reported a significance of P<0.01 with 
more than 1000 cases (or more than 20 000 participants 
for continuous outcomes). Weak (class IV) evidence was 
assigned to the remaining significant associations with 
P<0.05. For each association in the convincing or highly 
suggestive categories we reassessed the evidence after 
excluding the retrospective and case-control studies in 
an attempt to address reverse causality. Finally, for each 
association in the convincing category we reassessed 
the evidence after we examined each meta-analysis in 
depth by assessing the eligibility of the included studies 
as well as verifying the data used in the meta-analysis.
Evidence from meta-analyses of randomised con-
trolled trials was assessed in terms of the significance of 
doi: 10.1136/bmj.j2376 | BMJ 2017;357:j2376 | the bmj
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the summary effect (P<0.01, 0.01≤ P<0.05, P≥0.05), 95% 
prediction interval (excluding the null or not), and pres-
ence of large heterogeneity (I2 >50%), small study 
effects (P>0.10), and excess significance (P>0.10). We 
also noted the conclusions from any evidence classifi-
cation (GRADE27  or equivalent system) applied by the 
original meta-analyses. Finally, we assessed the evi-
dence from individual Mendelian randomisation stud-
ies for statistical significance of the effect estimate 
(P<0.01) and of the statistical power (>80%).28
For overlapping outcomes that were investigated in 
meta-analyses of observational studies and/or meta-anal-
yses of randomised controlled trials and/or individual 
Mendelian randomisation studies, we examined if the 
direction and statistical significance of the associations 
were reported concordantly across the different study 
types. We noted the overlapping outcomes that were 
graded as class I or II in meta-analyses of observational 
studies and had a 95% prediction interval excluding the 
null in meta-analyses of randomised controlled trials. For 
these outcomes we also presented the evidence from 
Mendelian randomisation studies if available.
Patient involvement
No patients were involved in setting the research ques-
tion or the outcome measures, nor were they involved in 
developing plans for design or implementation of the 
study. No patients were asked to advise on interpreta-
tion or writing up of results. There are no plans to dis-
seminate the results of the research to study participants 
or the relevant patient community. 
Results
literature review
Overall, the parallel reviews identified 4608 publica-
tions across three databases. After applying the inclu-
sion or exclusion criteria, 101 publications were 
selected for inclusion (fig 1 ). Specifically, 15 systematic 
reviews and 144 meta-analyses of observational studies 
were reported in 57 articles29-85 ; 31 meta-analyses of 
randomised controlled trials were reported in 8 arti-
cles86-93 ; and 107 Mendelian randomisation studies 
were reported in 36 articles (see tables S2 to S5, respec-
tively, in web appendix).94-129 Across all three study 
types, 136 unique outcomes were reported. 
Meta-analyses of observational studies
Overall, 144 meta-analyses of observational studies 
were identified (see table S3in web appendix). The 
median number of studies included in meta-analyses 
was 5 (range 2-31), the median number of participants 
was 7932 (129-1 017 810), and the median number of 
cases was 1176 (49-34 370). More than one meta-analysis 
was conducted for 16 outcomes (see table S3 in web 
appendix). The direction and statistical significance of 
the reported associations in overlapping meta-analyses 
were concordant for 14 (88%) outcomes: atrial fibrilla-
tion incidence (n=3),39 52 82  coronary heart disease 
(n=4),41 72 76 83  hypertension incidence (n=3),44 74 85  stroke 
incidence (n=2),48 75  diabetes (n=3),49 50 79  chronic kid-
ney disease (n=3),54 55 77  mild cognitive impairment 
(n=2),58 80  Parkinson’s disease (n=3),58 59 81  multiple 
sclerosis (n=2),60 78  coronary heart disease mortality 
(n=3),41 72 76  cardiovascular disease mortality (n=2),65 84 
stroke mortality (n=2),48 75  all cause mortality in 
patients with heart failure (n=2),43 67  and all cause mor-
tality in the general population (n=2).65 84  Discordance 
in the statistical significance was present for two out-
comes: diabetic neuropathy (n=2)51 53  and Alzheimer’s 
disease (n=4).57 58 73 80
After removing the overlapping meta-analyses (which 
were conducted in the same population for the same 
outcome), 76 unique meta-analyses were retained. The 
meta-analyses reported a wide range of outcomes (table 
1): cardiovascular outcomes (n=13), diabetes related out-
comes (n=9), kidney disorders (n=7), neurocognitive 
disorders (n=11), cancer outcomes (n=6), all cause or 
cause specific mortality (n=22), and other outcomes 
(n=8). Overall, 58 (76%) of the 76 non-overlapping 
meta-analyses reported nominally significant summary 
results (P<0.05). Figures 1 and 2 in the web appendix 
show the summary effects of the unique meta-analyses 
of observational studies. Of these, 12 (92%) meta-analy-
ses in cardiovascular outcomes, 8 (89%) in diabetes 
related outcomes, all 7 (100%) in  kidney disorders, 1 
(9%) in neurocognitive disorders, 1 (17%) in cancer out-
comes, 15 (68%) in all cause and cause specific mortal-
ity, and 6 (75%) in other outcomes reported summary 
estimates with P<0.05 and suggested that high levels of 
SUA were associated with an increased risk of disease. 
In addition, 7 (64%) meta-analyses in neurocognitive 
disorders and 1 (12%) in other outcomes (composite of 
adverse outcomes (death or major adverse cardiovascu-
lar event) in patients with acute ischaemic stroke) 
reported summary estimates with P<0.05 and suggested 
inverse associations with SUA level.
We then applied our evidence classification criteria. 
Sixteen (21%) meta-analyses had P<10−6, 10 (13%) had a 
95% prediction interval that excluded the null, 27 (36%) 
Publications identied from Medline, Embase, and Cochrane Library (n=4608)
Publications included (n=101):
  Observational studies (n=57; 10 systematic reviews and 47 meta-analyses)
  Meta-analyses of randomised controlled trials (n=8)
  Mendelian randomisation studies (n=36)
Publications eligible for full text review (n=445)
Excluded (n=344):
  Not systematic review, meta-analysis, or Mendelian randomisation study (n=183)
  Systematic review, meta-analysis, or Mendelian randomisation study not related
    to hyperuricemia or serum uric acid (n=31)
  Systematic review or meta-analysis about gout or prevalence, genetics of
    hyperuricemia, or serum uric acid (n=12)
  Systematic review of case report or series (n=6)
  Systematic review or meta-analysis of ecacy of serum uric acid lowering drugs
    (n=26)
  Meta-analysis of randomised controlled trials included non-drug intervention
    or antihypertension drugs (n=7)
  Publications not in English or Chinese (n=63)
  Abstract only (n=16)
Excluded (n=4163):
  Duplicate publications (n=402)
  Publications removed by title, abstract review (n=3761)
Fig 1 | study flowchart
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had more than 1000 cases (or more than 20 000 partici-
pants for continuous outcomes), 15 (20%) had no large 
heterogeneity (I2<50%), and 34 (45%) had neither small 
study effects nor excess significant bias. Based on these 
metrics, only one of 76 (1%) outcomes presented con-
vincing evidence (class I: stroke mortality in general 
population), 7 (9%) outcomes presented highly sugges-
tive evidence (class II: heart failure incidence, hyper-
tension incidence, impaired fasting glucose or diabetes, 
chronic kidney disease incidence, coronary heart dis-
ease mortality, all cause mortality in patients with heart 
failure, and non-alcoholic fatty liver disease), and 9 
(12%) outcomes presented suggestive evidence (class 
III: atrial fibrillation, coronary heart disease incidence, 
cardiovascular disease, prehypertension, medium term 
major adverse cardiac event, type 2 diabetes, cardiovas-
cular disease mortality, chronic kidney disease mortal-
ity, death, or cardiac events). The remaining 41 (54%) 
statistically significant outcomes presented weak evi-
dence (class IV).
We performed a thorough examination and reas-
sessed the meta-analyses of stroke mortality48  (class I) 
and found that data from the largest study were incor-
rect (the events represented stroke incidence cases 
rather than stroke deaths and the included study had 
not published data on stroke mortality).130  Further-
more, the data from two individual studies reported 
comparisons of SUA categories that differed from other 
studies (the highest sextile versus the second or third 
sextile rather than the lowest),131 132  and a fourth study 
had been using only data on ischaemic stroke deaths 
but missing the data on haemorrhagic stroke deaths.133 
When we excluded the stroke incidence study, used the 
proper comparison for the other two studies, and added 
the missing data in the fourth study, the association 
with stroke mortality was not statistically significant 
(table 2). For the highly suggestive outcomes (class II), 
when we limited the data to prospective cohort studies, 
all associations retained their ranking, except for all 
cause mortality in patients with heart failure and 
non-alcoholic fatty liver disease, which were down-
graded to class III (table X in the web appendix).
Meta-analyses of randomised controlled trials
We identified 31 meta-analyses of randomised con-
trolled trials on SUA lowering treatment from eight pub-
lications (see table S4 in web appendix). The median 
number of studies included in the meta-analyses was 5 
(range 2-10) and the median number of participants was 
216 (41-738). More than one meta-analysis was found for 
five outcomes (see table S4 in web appendix). The direc-
tion and statistical significance of the effects in overlap-
ping meta-analyses were in concordance only for one 
(20%) outcome: serum creatinine level (n=2).88 89  Dis-
cordance in either the direction and/or the statistical 
significance was found for the remaining four out-
comes: glomerular filtration rate (n=2),88 89  end stage 
kidney disease (n=2),88 89  systolic blood pressure 
(n=2),89 93  and diastolic blood pressure (n=2).89 93
Twenty unique meta-analyses (table 3) were identi-
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(n=10), endothelial function (n=2), all cause and cause 
specific mortality (n=4), and other outcomes (n=4). Fig-
ure 3 in the web appendix shows the summary effects of 
the unique meta-analyses of randomised controlled tri-
als. Overall, 12 (60%) reported a nominally significant 
summary result at P<0.05 (8 had P<0.001). Only three 
(15%) meta-analyses had a 95% prediction interval that 
excluded the null (two nephrolithiasis outcomes (with 
thiazide and citrate treatment) and one renal function 
outcome), 11 (55%) meta-analyses showed no large het-
erogeneity (I2<50%), and 13 (65%) meta-analyses 
showed neither small study effects nor excess signifi-
cant bias.
Only one outcome (recurrence of nephrolithiasis with 
citrates treatment) reported a P<0.001, had a 95% pre-
diction interval excluding the null, and had no evidence 
of large heterogeneity or bias. In the original meta-anal-
yses, the strength of evidence was graded collectively 
for three nephrolithiasis outcomes (thiazide, citrate, or 
allopurinol treatment) by using an approach conceptu-
ally similar to the GRADE ranking system,134 and evi-
dence for these three nephrolithiasis outcomes was 
graded as moderate.
Mendelian randomisation studies
A total of 107 Mendelian randomisation analyses were 
identified from 36 publications (see table S5 in web 
appendix). The median number of participants was 
7158 (range 343-206 822) and median number of cases 
was 2225 (19-65 877). The proportion of variance in SUA 
level (R2) explained by genetic instruments was 2-6%. 
More than one Mendelian randomisation study was 
identified for 14 outcomes (see table S5 in web appen-
dix). Discordance in either the direction and/or the sta-
tistical significance of association among overlapping 
Mendelian randomisation existed for all the identified 
outcomes: body mass index (n=7),95 96 101 102 110 115 121  bone 
mineral density in femoral neck (n=2),97 98  coronary 
heart disease (n=5),96 100 106 118 126  diastolic blood pres-
sure (n=7),96 101 106 110 119 121 124  systolic blood pressure 
(n=7),96 101 106 110 119 121 124  metabolic syndrome (n=2),107 120 
glucose level (n=3),96 106 121  triglyceride level (n=3),96 121 123 
diabetes (n=6),96 99 105 100 122 127  serum creatinine level 
(n=2),110 129  estimated glomerular filtration rate 
(n=5),106 110 121 128 129  Parkinson’s disease (n=5),111 112 116 117 125 
memory performance (n=2),114  and gout (n=3).99 100 106
The 56 unique outcomes (table 4) investigated in indi-
vidual Mendelian randomisation studies belonged to 
the following categories: anthropometric variables 
(n=9), cardiovascular outcomes (n=15), kidney disor-
ders (n=6), metabolic disorders (n=5), neurocognitive 
disorders (n=5), metabolites (n=11), all cause and cause 
specific mortality (n=3), and other outcomes (n=2). Only 
nine (16%) outcomes (diabetic macrovascular disease, 
arterial stiffness (internal diameter of carotid artery), 
adverse renal events, Parkinson’s disease, lifetime anx-
iety disorders, memory performance, cardiovascular 
disease mortality, sudden cardiac death, and gout) pre-
sented significant associations of P<0.05. Three Mende-
lian randomisation studies (on memory performance, 
Parkinson’s disease, and gout) reported discordant 
results in the direction and/or statistical significance in 
other Mendelian randomisation studies. Of note, only 
four outcomes (diabetic macrovascular disease, arterial 
stiffness (internal diameter of carotid artery), renal 
events, and gout) reported a P<0.01, and only that for 
gout was based on convincing evidence (P=3.55E-40, 
n=71 501, power >99%).
Comparison of findings from meta-analyses
Table 5 summarises the outcomes reported in 
meta-analyses of observational studies with highly 
 suggestive evidence or meta-analyses of randomised 
controlled trials with 95% prediction intervals exclud-
ing the null. Among these outcomes, hypertension and 
chronic kidney disease showed concordant evidence 
between meta-analyses of observational studies and 
the selected (largest) meta-analyses of randomised con-
trolled trials on their corresponding intermediate traits 
or surrogate outcomes (eg, systolic blood pressure, dia-
stolic blood pressure, serum creatinine level, estimated 
glomerular filtration rate, and end stage renal disease) 
but had discordant evidence from Mendelian randomi-
sation studies. Moreover, even for these outcomes there 
were additional meta-analyses of randomised con-
trolled trials that had found discordant effects in terms 
of direction and/or statistical significance for all these 
intermediate traits or surrogate outcomes, with the 
exception of serum creatinine level. Heart failure, 
impaired fasting glucose or diabetes, and coronary 
heart disease mortality showed no evidence from 
meta-analyses of randomised controlled trials, and 
Mendelian randomisation studies reported discordant 
evidence on the corresponding outcomes, the interme-
diate traits, or the surrogate outcomes. Recurrence of 
nephrolithiasis was only reported in meta-analysis of 
randomised controlled trials, and no evidence was 
found from meta-analyses of observational studies or 
Mendelian randomisation studies.
discussion
In this study, we provide a comprehensive overview of 
reported associations between serum uric acid (SUA) 
levels and a wide range of health outcomes by incorpo-
rating evidence from systematic reviews and meta- 
analyses of observational studies, meta-analyses of 
randomised controlled trials, and Mendelian randomi-
sation studies. We also further evaluated the reported 
evidence by following criteria that we have previously 
applied to appraise the epidemiological credibility in 
several research specialties.26 135 136 Our study comprised 
76 unique meta-analyses of observational studies, 20 
unique meta-analyses of randomised controlled trials, 
and 56 unique individual Mendelian randomisation 
studies, which overall covered 136 unique health 
 outcomes.
Main findings and possible explanations
Most health outcomes that were reported to be associ-
ated with SUA level were identified from meta-analyses 
of observational studies, but after the application of our 
criteria none of them were classified as convincing 
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(class I). Highly suggestive evidence (class II) existed for 
five health outcomes, including heart failure, hyperten-
sion, impaired fasting glucose or diabetes, chronic kid-
ney disease, and coronary heart disease mortality in the 
general population. Notably, a large proportion (80%) 
of the examined meta-analyses displayed substantial 
heterogeneity (I2>50%), indicating that these associa-
tions should be interpreted with caution. Possible 
sources of the observed heterogeneity include the mix-
ture of prospective, retrospective, or case-control stud-
ies and the mixture of different comparison groups, 
since some meta-analyses synthesised individual stud-
ies with diverse contrasted categories of SUA levels (eg, 
various choices of tertiles, quartiles, quintiles, or sex-
tiles of SUA levels). Likewise, although the outcomes 
with class I or II evidence fulfilled the criteria of credi-
bility assessment for meta-analyses of observational 
studies, it would be inadvisable to conclude causation 
on this basis alone, owing to the inherent limitations of 
unmeasured confounding, undetected bias, or reverse 
causality in observational studies. In relation to reverse 
causality for example, some of the associations that 
were initially classified as class II (eg, all cause mortal-
ity in patients with heart failure and non-alcoholic fatty 
liver disease), were no longer highly suggestive (and 
were downgraded to class III) when focusing on pro-
spective observational data and excluding the retro-
spective studies.
Current evidence from meta-analyses of randomised 
controlled trials was limited to the beneficial effects of 
SUA lowering treatment on some intermediate traits or 
biomarkers related to cardiovascular and renal disor-
ders (eg, blood pressure, endothelial functions, and 
renal function). However, when multiple meta-analyses 
of randomised controlled trials existed for traits or 
markers, often the results were not concordant in direc-
tion of effect and/or statistical significance. Although 12 
health outcomes had P<0.05, only recurrence of neph-
rolithiasis with citrate treatment achieved P<0.001, 
with 95% prediction interval excluding the null. 
Two  additional health outcomes (recurrence of 
 nephrolithiasis using thiazides and end stage renal dis-
ease in patients with coronary heart disease using allo-
purinol) also had a 95% prediction interval excluding 
the null. Large heterogeneity and evidence of bias were 
common even in meta-analyses of randomised con-
trolled trials (in 45% of meta-analyses and 35% of ran-
domised controlled trials). When incorporating 
evidence from meta-analyses of randomised controlled 
trials with that from meta-analyses of observational 
studies, there was a notable gap, as health outcomes 
that were investigated in meta-analyses of observa-
tional studies and classified as class I or II have gener-
ally not been evaluated in meta-analyses of randomised 
controlled trials. In a few cases, data from randomised 
controlled trials on surrogate outcomes (eg, systolic 
blood pressure, diastolic blood pressure, and renal 
function tests) that corresponded to disease outcomes 
in observational studies (hypertension, chronic kidney 
disease) were available, but conclusions from extrapo-
lation of surrogate outcomes, which were evaluated in 
short term trials, to long term clinical outcomes should 
be treated with caution.
As an alternative to randomised controlled trials, the 
Mendelian randomisation design has been developed 
for exploring the causal effect of biomarkers on health 
outcomes. Fifty six Mendelian randomisation studies 
were identified that explored the causal role of SUA in 
cardiovascular, metabolic, neurocognitive, and renal 
disorders or related traits and biomarkers. In contrast 
with the meta-analyses of observational studies where 
most of the results (76%) were significant at P<0.05, 
most (84%) health outcomes investigated in Mendelian 
randomisation studies were not statistically significant. 
The generally negative results across so many health 
outcomes suggest that the large effects have probably 
not been missed, but most of the included Mendelian 
randomisation studies could have been underpowered 
to detect modest effects. When retaining the largest 
Mendelian randomisation study for each health out-
come, significant results with P<0.05 were only reported 
for nine health outcomes, and only four of these health 




studies Meta-analysis of randomised controlled trials* Mendelian randomisation studies
Heart failure Class II NA Heart failure: n=22 926, P=0.51, power=0.11),
Hypertension† Class II Systolic blood pressure: P=0.001, 95% PI included 
null; diastolic blood pressure: P=0.03, 95% PI 
included null
Hypertension: n=3060, P=0.56, power=0.05
Impaired fasting glucose 
or diabetes
Class II NA Diabetes: n=165 482, P=0.79, power=0.06); fasting glucose: 
n=57 397, P>0.05; fasting insulin: n=19 899, P=0.99
Chronic kidney disease† Class II Serum creatinine: P<0.001, 95% PI included null; 
estimated glomerular filtration rate: P=0.010, 95% 
PI included null; end stage renal disease: P<0.001, 
95% PI excluded null
Chronic kidney disease: n=23 387; P=0.12, power=0.70; adverse renal 
events: n=755, P=0.01; serum creatinine: n=7979, P=0.07; estimated 
glomerular filtration rate: n=23 844, P=0.91, power=0.05
Coronary heart disease 
mortality†
Class II  
(general population)
NA Coronary heart disease incidence: n=206 822, P=0.49, power=0.57
Recurrence of 
nephrolithiasis
NA Citrates treatment: P<0.001, 95% PI excluded null; 
thiazides treatment: P<0.001, 95% PI excluded null
NA
NA=not applicable; PI=prediction interval. 
*Data presented on largest meta-analysis of randomised controlled trials for each outcome. 
†If there were no identical outcomes investigated in meta-analyses of randomised controlled trials and/or Mendelian randomisation studies to match with class I or II observational 
associations, the corresponding intermediate traits were juxtaposed as surrogates for comparison.
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outcomes (diabetic macrovascular disease, arterial 
stiffness (internal diameter of carotid artery), renal 
events, and gout) had P<0.01, whereas only the gout 
outcome was based on evidence from a Mendelian ran-
domisation study with adequate power. Of the other five 
health outcomes with P<0.05, Parkinson’s disease and 
memory performance had at least one other Mendelian 
randomisation study that was not significant or had an 
association in the opposite direction.
Several instrumental variable assumptions need to 
be fulfilled for the results of a Mendelian randomisa-
tion analysis to be valid. The first assumption states 
that the genetic instrument should be strongly associ-
ated with the intermediate phenotype. SUA level has 
an evident heritable component with an overall herita-
bility of 40-60%,137  but the strength of genetic instru-
ments used in Mendelian randomisation studies was 
small or moderate, accounting for only 2-6% of SUA 
variance. Currently, the proportion of SUA variance 
explained by all common genetic variants identified 
by a genome wide association study remains relatively 
small (7%).138 This limits the power of genetic instru-
ments to detect causal associations with SUA level. 
The second and third assumptions (the instrument is 
associated with the outcome through the studied 
exposure only and the genotype is independent of 
other factors that affect the outcome) are more difficult 
to evaluate given the largely unknown complexity and 
interconnectedness of biological pathways underlying 
the genetic variants related to SUA level. The included 
Mendelian randomisation studies tried to validate 
these assumptions either by excluding single nucleo-
tide polymorphisms related to other known confound-
ing factors, by excluding single nucleotide 
polymorphisms that had potential pleiotropic effects, 
or by applying new Mendelian randomisation meth-
ods to account for pleiotropic effects (eg, Egger Mende-
lian randomisation analysis or network Mendelian 
randomisation).
Clinical implications and future research
Current recommendations on the drug treatment of 
hyperuricemia are related to gout or nephrolithiasis.8 
Since a wide range of health outcomes has been identi-
fied to be associated with SUA level, a renewed interest 
in whether individuals with asymptomatic hyperurice-
mia should be treated with SUA lowering drugs for the 
prevention or treatment of associated cardiovascular 
and metabolic diseases. In this study we raised large 
uncertainty about the potential therapeutic benefits of 
an expansion of SUA lowering treatment. Although we 
identified some highly suggestive associations from 
observational studies, there was a lack of concordance 
with clinically relevant endpoints from randomised 
controlled trials or surrogate endpoints from Mende-
lian randomisation studies, and therefore evidence is 
insufficient to support any SUA lowering drug interven-
tion for these outcomes. Furthermore, the adverse 
effects of SUA lowering drugs should be taken into con-
sideration (eg, an estimated 0.1% of patients treated 
with allopurinol, the first line SUA lowering drug, 
develop allopurinol hypersensitivity syndrome, which 
can be life threatening).9
Our study does not support one of the recommenda-
tions in the recently updated European League Against 
Rheumatism gout treatment guidelines, which suggest 
that SUA level <3.0 mg/dL is not recommended for gout 
management in the long term.139  This recommendation 
is based on several observational studies in which low 
SUA levels were associated with increased risk of multi-
ple neurological diseases, including Alzheimer’s dis-
ease and Parkinson’s disease.140-142 However, in our 
umbrella review a number of meta-analyses reported 
nominally statistically significant associations of low 
SUA levels with increased risk of multiple neurological 
diseases, but several other meta-analyses (9 out of 28) 
did not support these findings. Moreover, our credibility 
assessment showed that the nominally significant asso-
ciations were consistent with class IV evidence, and a 
causal effect has not consistently been established for 
any neurological disease in Mendelian randomisation 
studies. Therefore, there is no adequate evidence 
against lowering SUA levels in patients with gout 
because of an increased risk of neurological diseases.
For future research, efforts to address the limitations 
and caveats in current evidence will be beneficial. In 
particular, as the current clinical trials of SUA lowering 
treatment largely focus on the effect of allopurinol on 
some intermediate traits or biomarkers, the effect of 
SUA reduction on clinically relevant endpoints of the 
convincing and highly suggestive associations might be 
worth further investigation. In addition, efforts to eval-
uate whether other SUA lowering agents have the same 
effect as xanthine oxidase inhibitors will help to deter-
mine if these effects are truly due to the SUA reduction 
itself rather than the mechanisms of xanthine oxidase 
inhibition. Finally, noting the largely discordant evi-
dence in Mendelian randomisation studies, better 
designed such studies with collaboration of large inter-
national consortiums might assist in deciding whether 
the lack of replication of highly suggestive findings of 
observational studies is owing to low power to detect 
moderate or small effects, or owing to truly negative 
effects.
strengths and weaknesses of this review
The strengths of umbrella reviews have been described 
in detail.26 135 136 Here we summarised and presented the 
evidence of the associations between SUA level and a 
wide spectrum of health related outcomes systemati-
cally and thoroughly by incorporating information from 
meta-analyses of observational studies, meta-analyses 
of randomised controlled trials, and Mendelian 
 randomisation studies. We then calculated a number of 
additional metrics and applied well defined criteria to 
assess the credibility of the observed associations.
In relation to study weaknesses, umbrella reviews 
focus on existing meta-analyses and therefore out-
comes that were not assessed in a meta-analysis are not 
included in the review. For example, we found no for-
mal meta-analysis of observational studies on SUA level 
and urolithiasis or gout, even though these associations 
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are well established. Although there are some differ-
ences in SUA levels between men and women, there is 
not sufficient evidence at a meta-analysis level and 
therefore we did not attempt to perform subgroup anal-
yses by sex. To avoid subjectivity, we did not include 
reviews without explicit systematic literature searches, 
but this could limit the breadth of the results to some 
extent, if some non-systematic reviews cover questions 
that have not been addressed by systematic 
reviews.143 144 Furthermore, we did not appraise the 
quality of the individual studies, since this should be 
the responsibility of the authors of the original 
meta-analysis and it was beyond the scope of the cur-
rent umbrella review.
We adopted credibility assessment criteria, which 
were based on established tools for observational evi-
dence, and their individual limitations have been sum-
marised previously.26 135 136 None of the components of 
these criteria provides firm proof of lack of reliability, 
but they cumulatively map the possibility that the 
results are susceptible to bias and uncertainty. Given 
the wide variety of study designs and populations con-
sidered in several of the meta-analyses, one might claim 
that large heterogeneity in particular may not necessar-
ily be worrisome. However, considering it is difficult to 
differentiate the real heterogeneity from the heteroge-
neity that reflects some forms of bias or uncertainty, we 
applied I2<50% as one of the criteria for class I evidence 
(convincing) for meta-analyses of observational stud-
ies, so as to assign the top evidence grade only to asso-
ciations that are most robust and without hints of bias. 
In most cases I2>50% indicates the presence of compo-
nent studies with opposite effects or of component 
studies with and without statistically significant associ-
ations. However, nine meta-analyses of observational 
studies classified as class II, III, or IV had an I2>50%, 
with all component studies reporting a statistically sig-
nificant association of the same direction. Only one of 
these nine meta-analyses (heart failure incidence) 
would be upgraded from class II to class I if we did not 
consider the heterogeneity criterion, since the other 
eight also failed additional class I criteria. No 
meta-analyses of randomised controlled trials had an 
I2>50% with all component studies reporting a statisti-
cally significant association with the same direction.
Finally, another limitation of the umbrella review 
approach is the use of existing meta-analyses taking 
their results at face value. Meta-analyses are known to 
have common flaws145  and their results may also 
depend on choices made about what estimates to select 
from each primary study and how to represent them in 
the meta-analysis (eg, in what contrast of exposure 
 levels). This may be a common problem when the factor 
of interest is continuous, as in the case of SUA level, and 
where different comparisons of levels of the risk factor 
may be selected to express risk.146 We therefore decided 
to investigate any meta-analyses with seemingly con-
vincing evidence in more detail. In this process, the 
only meta-analysis that seemed to achieve convincing 
evidence (class I: stroke mortality) was found to actu-
ally have major flaws. Recalculation of the results 
showed that the evidence was downgraded to not sta-
tistically significant. It is possible that similar thorough 
evaluations might have downgraded the credibility of 
some additional meta-analyses. In addition, we noted 
that many primary studies are represented in the calcu-
lations of meta-analyses by using only a small subset of 
the data of extreme groups (eg, as the risk ratio for an 
event in extreme quintiles of SUA levels). In these cases, 
the number of events pertinent to these extreme groups 
may be much fewer than the total number of events 
used in calculating the amount of evidence criteria. 
Therefore, some meta-analyses that seemingly include 
studies with more than 1000 cases may actually capture 
fewer than 1000 cases in the main calculations and 
thus their grading appraisal should have been weaker. 
These flaws and deficiencies are difficult to decipher 
without a thorough reconstruction of all observational 
meta-analyses, and they may explain why observa-
tional evidence for SUA associations generally did not 
show good concordance with evidence from ran-
domised controlled trials and Mendelian randomisa-
tion studies in our umbrella evaluation.
Meta-analyses of observational data for SUA level 
and other risk factors need to be strengthened. For con-
tinuous putative risk factors such as SUA concentra-
tion, a consensus on the categorisation of levels of 
interest would be useful. This might be achieved by 
careful meta-analyses of individual level data in inclu-
sive consortiums. This approach would allow a more 
accurate and reliable exploration of both linear and 
non-linear associations (eg, the possibility of U-shaped 
associations with increased risk at both very high and 
very low levels). Currently available data from 
meta-analyses do not allow for consistent handling and 
assessment of such non-linear relations. Conversely, 
data dredging using different categorisations of SUA 
levels for comparison is likely to fuel a literature with 
spurious associations.147
Conclusion
This comprehensive umbrella review will help investi-
gators to judge the relative priority of health outcomes 
related to SUA level for future research and clinical 
management of disease. In summary, despite a few 
hundred systematic reviews, meta-analyses, and Men-
delian randomisation studies exploring 136 unique 
health outcomes, convincing evidence of a clear role of 
SUA level only exists for gout and nephrolithiasis. Con-
cordant evidence between observational studies and 
randomised controlled trials existed for hypertension 
and chronic kidney disease, but a potential causal role 
of SUA level for these outcomes has not been verified by 
current Mendelian randomisation studies and even for 
these two outcomes not all meta-analyses of ran-
domised controlled trials are concordant among them-
selves and with observational evidence. Therefore, the 
available evidence does not support any change in the 
existing clinical recommendations in relation to hyper-
uricemia.
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